Luvox CR Symptom Benefit Claims Draw DDMAC Warning
Executive Summary
An FDA warning letter to Jazz Pharmaceuticals citing a Luvox CR (fluvoxamine maleate) patient brochure continues an agency trend of targeting efficacy claims about individual symptoms of a broader disease state
You may also be interested in...
Jazz Buys Compliance Trouble With FazaClo Acquisition
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.
Rx Promotional Campaign Based On Individual Symptoms Gives FDA Allergic Reaction
Meda’s allergic rhinitis drug Astepro (azelastine) draws an FDA letter for a telephone sales script that focused on the drug’s effect on nasal congestion, which was not studied separately from its effect on other symptoms.
Patient Who Wouldn't Be Here Without Axcan's Photofrin Should Disappear Now, FDA Says
Web videos featuring overblown patient testimonials prove an easy target for DDMAC.